McCulloch, R;
Lewis, D;
Crosbie, N;
Eyre, TA;
Bolam, S;
Arasaretnam, A;
Creasey, T;
... Rule, S; + view all
(2021)
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
British Journal of Haematology
10.1111/bjh.17363.
Preview |
Text
bjh.17363.pdf - Published Version Download (376kB) | Preview |
Abstract
Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed to investigate outcomes and tolerability for ibrutinib when given second line in a real‐world setting. Our multicentre retrospective analysis included 211 R/R MCL patients, median age 73 years, receiving ibrutinib second‐line within the United Kingdom’s National Health Service. Overall response to ibrutinib was 69% (complete response 27%). The median progression‐free survival (PFS) was 17·8 months (95% CI 13·1–22·2) and median overall survival (OS) 23·9 months (95% CI 15·0–32·8). Drug‐related adverse event led to dose reduction in 10% of patients and discontinuation in 5%. In patients with progressive disease, accounting for 100 of 152 patients stopping ibrutinib, 43% received further systemic therapy. Post‐ibrutinib rituximab, bendamustine and cytarabine (R‐BAC) showed a trend toward improved survival compared to alternative systemic treatments (post‐ibrutinib median OS 14·0 months, 95% CI 8·1–19·8, vs. 3·6 months, 95% CI 2·6–4·5, P = 0·06). Our study confirms the clinical benefit and good tolerability of ibrutinib at first relapse in a real‐world population. Patients progressing on ibrutinib had limited survival but outcomes with R‐BAC in select patients were promising.
| Type: | Article |
|---|---|
| Title: | Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bjh.17363 |
| Publisher version: | http://dx.doi.org/10.1111/bjh.17363 |
| Language: | English |
| Additional information: | ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| Keywords: | ibrutinib, mantle cell lymphoma, post-ibrutinib outcomes, clinical aspects |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10124235 |
Archive Staff Only
 |
View Item |
